Growth hormone is essential for sustaining longitudinal growth in man. However, during the last 20 years, it has become evident that the actions of growth hormone, at a cellular level, are mediated by specific growth promoting factors.
This paper describes the nature and actions of mammalian growth factors and summarises the immense contribution that the measurement of these substances has made towards the elucidation of many problems in the science of human growth and development.
Get full access to this article
View all access options for this article.
References
1.
LevintowLEagleH. Biochemistry of cultured mammalian cells. Annu Rev Biochem1961; 30: 605–640.
2.
EllisSHubleJSimpsonME. Influence of hypophysectomy and growth hormone on cartilage sulphate metabolism. Proc Soc Exp Biol Med1953; 84: 603–605.
3.
SalmonWDDaughadayWH. A hormonally controlled factor which stimulates sulphate incorporation by cartilage in vitro. J Lab Clin Med1957; 49: 825–835.
4.
DaughadayWHSalmonWDAlexanderF. Sulphation factor activity of sera from patients with pituitary disorders. J Clin Endocrinol Metab1959; 19: 743–758.
5.
HallK. Quantitative determination of the sulphation factor activity in human serum. Acta Endocrinol (Copenh)1970; 63: 338–350.
6.
Van den BrandeJLDu CajuMVL. An improved technique for measuring somatomedin activity in vitro. Acta Endocrinol (Copenh)1974; 75: 233–242.
7.
DaughadayWHReederC. Synchronous activation of DNA synthesis in hypophysectomised rat cartilage by growth hormone. J Lab Clin Med1966; 68: 357–368.
8.
DaughadayWHMarizIKConversion of Proline-u-C14 to labelled hydroxyproline by rat cartilage in vitro. Effects of hypophysectomy, growth hormone and Cortisol. J Lab Clin Med1962; 59: 741–752.
9.
SalmonWDDu VallMR. A serum fraction with ‘Sulphation factor activity’ stimulates in vitro incorporation of leucine and sulphate into protein polysaccharide complexes, uridine into DNA and thymidine into DNA of costal cartilage from hypophysectomised rats. Endocrinology1970; 86: 721–727.
10.
Van WykJJHallKWeaverRP. Partial purifaction of sulphation factor and thymidine factor from plasma. Biochim Biophys Acta1969; 192: 560–562.
11.
RallTWWosilaitWDSutherlandEW. The relationship of epinephrine and glycogen to liver phosphorylase (iii). J Biol Chem1956; 218: 483–495.
12.
RallTWSutherlandEWBerthetJ. The relationship of epinephrine and glycogen to liver phosphorylase (iv). J Biol Chem1957; 224: 463–475.
13.
GeyGOThalhimerW. Observations on the effect of the addition of insulin into the medium of tissue culture. JAMA1924; 82: 1609.
DaughadayWHHallKRabenMSSalmonWDVan den BrandeJLVan WykJJ. Somatomedin: Proposed designation for sulphation factor. Nature1972; 235: 107.
16.
SalmonWD. Investigation with a partially purified preparation of serum sulphation factor: lack of specificity for cartilage sulphate. Proceedings of the Second International Symposium on Growth Hormones 1971. Eds PecileEMullerEE. Amsterdam: Excerpta Medica1972; Section 3: 180.
17.
UthneKUthneT. Influence of liver resection and regeneration on somatomedin (sulphation factor) activity in sera from normal and hypophysectomised rats. Acta Endocrinol (Copenh)1972; 71: 255–264.
18.
McConagheyPSledgeOBK. Production of ‘sulphation factor’ by the perfused liver. Nature1970; 225: 1249–1250.
19.
McConagheyP. The production of ‘sulphation factor’ by rat liver. J Endocrinol1972; 52: 1–9.
20.
HallKUthneK. Some biological properties of purified sulphation factor from human plasma. Acta Med Scand1971; 190: 137–143.
21.
McConagheyPDehnelJ. Preliminary studies of ‘sulphation factor’ production by rat kidney. J Endocrinol1972; 52: 587–588.
22.
HallK. Human somatomedin. Acta Endocrinol (Suppl) (Copenh)1972; 163: 1–45.
23.
UthneK. Human somatomedins. Acta Endocrinol (Suppl) (Copenh)1973; 175: 1–35.
24.
FryklundLSievertssonH. Primary structure of somatomedin-B: A growth hormone dependent serum factor with protease inhibiting activity. FEBS Lett1978; 87: 55–60.
25.
Van WykJJUnderwoodLEHintzRLVoinaSJWeaverRP. The somatomedins: a family of insulin-like hormones under growth factor control. Recent Prog Horm Res1974; 30: 259–318.
26.
MosesACNissleySPCohenKLRechlerMM. Specific binding of a somatomedin-like polypeptide in rat serum depends on growth hormone. Nature1976; 263: 137–140.
27.
FroeschIERBurgiHRamseierEBBallyPLabhartAAntibody suppressible and non-suppressible insulin-like activities in human serum and their physiologic significance. J Clin Invest1963; 42: 1816–1834.
28.
ZapfJSchoenleEFroeschERInsulin-like growth factors I and II. Eur J Biochem1978; 87: 285–296.
29.
OelzOFroeschERBunzliHFHumbelRERitschandWU. In: SteinerDFFreinkelN, eds. Handbook of Physiology, Washington: American Physiological Society1979; 1: 685.
30.
ZinggAEFroeschER. Effects of partially purified preparation with non-suppressible insulin-like activity (NSILA-S) on sulphate incorporation into rat and chicken cartilage. Diabetologia1973; 9: 472–476.
31.
FroeschERZapfJMeuliCBiological properties of NSILA-S. Adv Metab Disord1975; 8: 211–235.
32.
CohenS. Isolation of a mouse submaxillary gland protein accelerating incisor eruption and eyelid opening in the new-born animal. J Biol Chem1962; 237: 1555–1562.
33.
CohenSTaylorJM. Epidermal growth factor: chemical and biological characterisation. Recent Prog Horm Res1974; 30: 533–550.
34.
CohenSSavageCR. Recent studies on the chemistry and biology of epidermal growth factor. Recent Prog Horm Res1974; 30: 551–574.
35.
Levi-MontalciniRHamburgerV. A diffusible agent of mouse sarcoma producing hyperplasia of sympathetic ganglia and hyperneurotization of viscera in the chick embryo. J Exp Zool1953; 123: 233–278.
36.
WinickMGreenbergRL. Appearance and localization of a nerve growth-promoting protein during development. Pediatrics1965; 35: 221–228.
37.
CohenS. Purification of a nerve growth promoting protein from the mouse salivary gland and its neuro-cytotoxic antiserum. Proc Natl Acad Sci USA1960; 46: 302–311.
LongoAPenhoetE. Nerve growth factor in rat glioma cells. Proc Natl Acad Sci USA1974; 71; 2347–2349.
40.
BergerBDWiseCJSteinL. Nerve growth factor: enhanced recovery of feeding after hypothalamic damage. Science1973; 180; 506–508.
41.
GospodarowiczDRudlandPLindstromJPenirschkeK. Fibroblast growth factor: localisation, purification, mode of action and significance. Adv Metab Disord1975; 8: 301–335.
42.
DulakNTeminH. Multiplication stimulating activity for chicken embryo fibroblasts from rat liver cell conditioned medium: a family of small polypeptides. J Cell Physiol1973; 81: 153–160.
43.
RechlerMMPodskalnyJMNissleySP. Interaction of multiplication stimulating activity with chick embryo fibroblasts demonstrates a growth receptor. Nature1976; 259: 134–136.
44.
KatoYNasuNTakaseTSuzukeF. Demonstration of somatomedin activity of ‘Multiplication stimulating activity’ in rabbit costal cartilage in culture. J Biochem (Tokyo)1978; 84: 1001–1004.
45.
HallKBrandtJEnbergGFryklundL. Immunoreactive somatomedin-A in human serum. J Clin Endocrinol Metab1979; 48: 271–278.
46.
YalowRSHallKLuftR. Radioimmunoassay of somatomedin-B. Application to chemical and physiologic studies. J Clin Invest1975; 55: 127–137.
47.
FurlanettoRWUnderwoodLEVan WykeJJD'ErcoleAJ. Estimation of somatomedin-C levels in normals and patients with pituitary disease by radioimmunoassay. J Clin Invest1977; 80: 648–657.
MarshallRNUnderwoodLEVoinaSJFousheeDBVan WykJJ. Characterization of the insulin and somatomedin-C receptors in human placental cell membranes. J Clin Endocrinol Metab1974; 39: 283–292.
52.
DaughadayWH. ‘Postsession discussion’- Somatomedins and some other growth factors. 28th Nobel Symposium, Sweden (1974). Advances in Metabolic Medicine1975; 8: 409.
53.
GiordanoGFoppianiEMinutoFPerroniD. Growth hormone and somatomedin behaviour in the newborn. Acta Endocrinol (Copenh)1976; 81: 449–453.
54.
AlmqvistSRuneI. Studies on sulphation factor activity of human serum. Acta Endocrinol (Copenh)1961; 36: 566–576.
55.
RothenbergLHHintzRVan CampM. Assessment of physical maturity and somatomedin levels during puberty. Am J Orthod1977; 71: 666–677.
56.
Van den BrandeJL. Plasma somatomedin. Clinical observations. In: PecileAMullerEE, eds. Growth hormone and related peptidesExcerpta Medica, Amsterdam1976: 271–285.
57.
HallKOlinP. Sulphation factor activity and growth rate during long-term treatment of patients with pituitary dwarfism with human growth hormone. Acta Endocrinol (Copenh)1972; 69: 417–433.
58.
Van den BrandeJLDu CajuMVL. Plasma somatomedin activity in children with growth disturbances. In: RaitiS, eds, Advances in Human Growth Hormone Research. BethesdaDHEW Publ.1974: 98.
59.
HallKFilipssonR. Correlation between somatomedin-A in serum and body height development in healthy children and certain children with growth disturbances. Acta Endocrinol (Copenh)1975; 78: 239–250.
HintzRLSuskindRAmatayakulKThanangkulOOlsonR. Plasma somatomedin and growth hormone values in children with protein-calorie malnutrition. J Pediatr1978; 92: 153–156.
62.
MohanPSRaoKS Jaya. Plasma somatomedin activity in protein calorie malnutrition. Arch Dis Child1979; 54: 62–64.
HortonWARimoinDLUnderwoodLEVan WykJJ. Serum somatomedin-C in achondroplasia. N Eng J Med1976; 295: 453–454.
69.
GiordanoGFoppianiEMinutoF Human growth hormone, immunoreactive insulin and somatomedin activity in achondroplasia. In GeddaLParisiP eds. Auxology: human growth in health and disorder. London: Academic Press1978: 253.
70.
MorabitoFCaiazzaFBarrecaAHuman growth hormone, immunoreactive insulin and somatomedin activity in Turner's syndrome. In: GeddaLParisiP, eds. Auxology: human growth in health and disorder. London: Academic Press1978; 261.
71.
TakanoKHallKRitzenMIseliusLSievertssonH. Somatomedin-A in human serum, determined by radioreceptor assay. Acta Endocrinol (Copenh)1976; 82: 449–459.
72.
DaughadayWHParkerML. Sulphation factor measurement as an aid in the recognition of pituitary dwarfism. J Clin Endocrinol Metab1963; 23: 638–650.
73.
TakanoKHizukaNShizumeKHayashiNMotoikeYObataH. Serum somatomedin peptides measured by somatomedin-A radioreceptor assay in chronic liver disease. J Clin Endocrinol Metab1977; 45: 828–832.
74.
EldersMJWingfieldBSMcNattMLClarkeJSHughesER. Glucocorticoid therapy in children. Effect on somatomedin secretion. Am J Dis Child1975; 129: 1393–1396.
PhilipsLSVassilopoulou-SellinR. Nutritional regulation of somatomedin. Am J Clin Nutr1979; 32: 1082–1096.
77.
KastrupKWAndersenHJLebechP. Somatomedin in newborns and the relationship to human chronic somatotrophin and fetal growth. Acta Paediatr Scand1978; 67: 757–762.
78.
GluckmanPDBrinsmeadMW. Somatomedin in cord blood: relationship to gestational age and birth size. J Clin Endocrinol Metab1976; 43: 1378–1381.
79.
D'ErcoleAJFousheeDBUnderwoodLE. Somatomedin-C receptor iogeny and levels in porcine fetal and human cord serum. J Clin Endocrinolol Metab1976; 43: 1069–1077.
80.
LaronZPertzelanAMannheimerS. Genetic pituitary dwarfism with high serum concentration of growth hormone: a new inborn error of metabolism? Isr J Med Sci1966; 2: 152–155.
81.
DaughadayWHLaronZPertzelanAHeinsJ. Defective sulphation factor generation: a possible etiological link in dwarfism. Trans Assoc Am Physicians1969; 82: 129–140.
82.
LaronZPertzelanAKarpMSilbergeldA KowadloDaughadayWH. Administration of growth hormone to patients with familial dwarfism with high plasma immunoreactive growth hormone: measurement of sulphation factor, metabolic and linear growth responses. J Clin Endocrinol Metab1971; 33: 332–342.
RabinowitzDMerimeeTJ. Isolated human growth hormone deficiency and related disorders. Isr J Med Sci1973; 9: 1601–1657.
85.
HoffenbergRHowellSEpsteinSIncreasing growth and raised circulating somatomedin but normal immunoassayable growth hormone. Clin Endocrinol1977; 6: 443–448.
86.
WiedemannESchwartzEFrantzAG. Acute and chronic estrogen effects upon serum somatomedin activity, growth hormone and prolactin in man. J Clin Endocrinol Metab1976; 42: 942–952.
87.
McCullaghEPBeckJCSchaffenburghCA. Control of diabetes and other features of acromegaly following treatment with estrogens. Diabetes1955; 4: 13–23.
88.
GluckmanPDHoldawayIM. Prolactin and somatomedin studies in the syndrome of growth hormone independent growth. Clin Endocrinol1976; 5: 545–549.
89.
BursteinPJSchalchDSHeinrichVEJohnsonCJ. The effects of hypothyroidism on somatomedinI GF (insulin-like growth factor). Clinical Research1978; 26: 411a.
90.
BursteinPJDrazninRJohnsonCJSchalchDS. The effects of hypothyroidism on growth serum growth hormone, the growth hormone-dependent somatomedin, insulin-like growth factor and its carrier protein in rats. Endocrinology1979; 104: 1107–1111.
91.
SchalchDSHeinrichUEDrazninBJohnsonCJMillerLL. Role of the liver in regulating somatomedin activity: hormonal effects on the synthesis and release of insulin-like growth factor and its carrier protein by the isolated perfused rat liver. Endocrinology1979; 104: 1143–1151.
92.
DaughadayWHKapadiaM. Maintenance of serum somatomedin activity in hypophysectomised pregnant rats. Endocrinology1978; 102: 1317–1320.
93.
BalaRMBohnetHGCarterJNFriesenHG. Effects of prolactin on serum somatomedin in hypophysectomised rats. Clinical Research1976; 24: 655a.
94.
HolderATWallisM. Actions of growth hormone, prolactin, and thyroxine on serum somatomedin-like activity and growth in pituitary dwarf mice. J Endocrinol1977; 74: 223–229.
95.
WernerSHallKSjobergHE. Bromocriptine therapy in patients with acromegaly: effects on growth hormone somatomedin-A and prolactin. Acta Endocrinol (suppl) (Copenh)1978; 216: 88, 199–206.
96.
Van BuulSVLDumoleignAMKortelandPVan de KlunderTVan den BrandeJL. The snell-dwarf mouse: Interrelationship of growth in length and weight, serum somatomedin activity, and sulphate incorporation in costal cartilage during growth hormone and thyroxine treatment. Proceedings of the International Symposium on Somatomedins and Growth. Santa Margherita, Italy New York: Academic Press1978.
